The 340B Drug Pricing Program helps eligible healthcare organizations access outpatient drugs at discounted prices. But managing the program requires careful attention to eligibility, patient definitions, purchasing records, inventory, and compliance controls. Even a small process gap can create problems during a 340B audit.
For covered entities, the goal is not simply to participate in the program. It is to maintain accurate records, monitor transactions, and make sure 340B rules are followed consistently.
What Are Common 340B Compliance Mistakes?
Most 340B compliance mistakes come from weak processes rather than intentional errors. Common problems include incorrect patient eligibility, duplicate discounts, inaccurate inventory records, and poor oversight of contract pharmacies.
Here are some of the issues organizations should watch closely.
1. Using 340B Drugs for Ineligible Patients
One of the most important requirements is making sure discounted drugs are used only for eligible patients of the covered entity.
A common mistake is assuming that every patient treated by an organization automatically qualifies. Patient eligibility depends on the relationship between the patient, the covered entity, and the healthcare services provided.
Organizations should have clear procedures for identifying eligible patients and reviewing exceptions. Staff should also understand how patient eligibility is determined instead of relying only on assumptions or manual checks.
2. Poor Inventory and Transaction Tracking
340B programs can involve large numbers of prescriptions, providers, locations, products, and dispensing transactions. When these records are managed manually or across disconnected systems, errors become easier to miss.
For example, an organization may have difficulty matching a prescription to the correct inventory source or identifying discrepancies between purchasing and dispensing records.
Strong 340B program management depends on consistent data. Organizations should maintain reliable records for purchases, dispensing, replenishment, and adjustments.
3. Failing to Prevent Duplicate Discounts
Duplicate discounts are another major 340B compliance risk.
A duplicate discount can occur when the same drug transaction receives a 340B discount while also generating a Medicaid rebate. The program requires covered entities to have controls that help prevent this situation.
Organizations should regularly review their Medicaid billing arrangements, state-specific requirements, and claims data. Automated checks can also help identify transactions that need further review.
4. Weak Contract Pharmacy Oversight
Contract pharmacies can make 340B operations more flexible, but they also add another layer of complexity.
Covered entities need appropriate oversight of contract pharmacy arrangements. This includes monitoring claims, patient eligibility, dispensing activity, inventory, and other relevant records.
A common mistake is treating the contract pharmacy as a separate responsibility and assuming that compliance is being handled automatically. The covered entity remains responsible for managing its 340B program properly.
Regular reviews and clearly defined responsibilities can reduce this risk.
5. Incomplete or Inaccurate Records
Good documentation is essential for 340B compliance and audit readiness.
Organizations may run into problems when records are incomplete, inconsistent, or difficult to retrieve. This can include missing transaction details, outdated policies, unclear eligibility documentation, or inconsistent information across systems.
A better approach is to establish a documentation process that is part of everyday operations. Records should be organized, accessible, and reviewed regularly rather than prepared only when an audit is approaching.
6. Not Monitoring Changes in the Program
340B requirements and operational expectations can change. Organizations that rely on old procedures without reviewing them may create unnecessary compliance risks.
Staff responsible for the program should stay informed about relevant regulatory updates, organizational changes, and internal process changes.
For example, adding a new site, changing pharmacy arrangements, or modifying billing processes may require a review of existing 340B procedures.
7. Relying Too Much on Manual Processes
Manual spreadsheets and disconnected systems can work for smaller operations, but they become harder to manage as transaction volume grows.
Manual processes can lead to duplicate entries, calculation errors, missing records, and delayed reporting. They can also make it difficult to identify patterns across thousands of transactions.
This is where 340B compliance technology can help.
Modern tools can support data validation, transaction monitoring, exception reporting, and audit preparation. Technology does not replace human oversight, but it can make routine monitoring more consistent and easier to manage.
How Technology Can Improve 340B Compliance
Technology can bring different sources of 340B data into a more organized workflow. Instead of reviewing every transaction manually, compliance teams can use automated rules to identify transactions that may need attention.
For example, a compliance system may help flag:
-
Potential patient eligibility issues
-
Duplicate or unusual transactions
-
Inventory discrepancies
-
Missing data
-
Contract pharmacy exceptions
-
Medicaid-related concerns
-
Unusual purchasing or dispensing patterns
This type of 340B monitoring gives teams a clearer view of where problems may exist.
Organizations looking to strengthen their compliance processes can also explore specialized 340B program management and health technology solutions that support data review, monitoring, and operational oversight.
Building Better 340B Audit Readiness
Audit readiness should not be a last-minute project. A strong organization treats it as an ongoing process.
Start by creating a regular internal review schedule. Check patient eligibility, purchasing records, inventory controls, contract pharmacy activity, and other key areas based on the organization's risk profile.
It also helps to document corrective actions. If an issue is discovered, record what happened, why it happened, and what was done to prevent it from happening again.
This creates a stronger compliance culture and gives leadership better visibility into program performance.
Practical Ways to Reduce 340B Compliance Risks
A few simple practices can make a meaningful difference:
Create clear policies. Staff should know how the organization handles eligibility, purchasing, dispensing, inventory, and other 340B processes.
Review data regularly. Do not wait for an audit to discover unusual transactions or missing information.
Use automated validation where possible. Technology can reduce repetitive manual checks and highlight exceptions faster.
Train the right people. Pharmacy, billing, finance, compliance, IT, and clinical teams may all influence 340B operations.
Document corrective actions. Keep a record of identified issues and the steps taken to address them.
Review contract pharmacy activity. Contract arrangements need ongoing oversight, not just an initial setup review.
Test internal controls. Periodic testing can reveal weaknesses before they become larger compliance problems.
What Should Organizations Review for 340B Compliance?
A practical review should cover several areas:
-
Covered entity eligibility – Confirm that the organization and applicable sites remain eligible.
-
Patient eligibility – Verify that 340B drugs are associated with eligible patients.
-
Purchasing records – Check that purchases are properly documented.
-
Inventory controls – Look for discrepancies between inventory, purchasing, and dispensing data.
-
Duplicate discounts – Review processes designed to prevent duplicate discounts.
-
Contract pharmacies – Monitor transactions and compliance controls.
-
Policies and training – Make sure procedures are current and staff understand their responsibilities.
-
Audit documentation – Keep records organized and available for review.
Frequently Asked Questions
What is the biggest 340B compliance risk?
There is no single risk that applies equally to every organization. Patient eligibility, duplicate discounts, inventory controls, contract pharmacy oversight, and inaccurate records are all areas that can create compliance concerns.
How often should 340B compliance be reviewed?
Organizations should use ongoing monitoring rather than relying on a single annual review. The right frequency depends on transaction volume, program complexity, internal controls, and identified risks.
Can technology prevent all 340B compliance mistakes?
No. Technology can improve data validation, monitoring, reporting, and exception management, but organizations still need appropriate policies, trained staff, and human oversight.
Conclusion
340B compliance depends on accurate data, clear processes, and regular oversight. The most effective approach is to identify potential problems early instead of waiting for an audit to expose them.
By combining strong internal controls with appropriate technology, healthcare organizations can improve 340B program management, strengthen audit readiness, and reduce avoidable compliance risks.
